Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
复制标题
DOI：
10.1093/cid/ciac796
复制
发表时间：
2023-01-13
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
接受抗逆转录病毒治疗（ART）的人类免疫缺陷病毒（HIV）感染者CD4 t细胞计数良好，在接种严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）疫苗后产生有效的免疫反应。关于长期反应和加强剂量影响的数据很少。成年艾滋病毒感染者被纳入一项单臂开放标签研究。两剂ChAdOx1 nCoV-19疫苗接种12个月后，再接种第三剂异源疫苗。参与者ART检测不到病毒血症，CD4细胞计数为350个/µL。通过抗刺突免疫球蛋白G （IgG）酶联免疫吸附试验（ELISA）、MesoScale Discovery （MSD）抗刺突平台、ACE-2抑制、激活诱导标记（AIM）试验和t细胞增殖检测对祖先菌株和相关变异株的免疫应答。总共有54名参与者接受了2剂ChAdOx1 nCoV-19。43人在第一次注射后1年接受第三次注射（42人使用BNT162b2, 1人使用mRNA-1273）。第三次给药后，抗sars - cov -2总刺突IgG滴度（MSD）、ACE-2抑制和IgG ELISA结果均显著高于第182天滴度（P < 0.0001）。AIM检测的针对SARS-CoV-2 S1和S2肽库的SARS-CoV-2特异性CD4+ t细胞反应在第三次疫苗接种后与第一次接种后6个月相比显著增加，增强后对SARS-CoV-2 S1和S2的增殖性CD4+和CD8+ t细胞反应显著增加。对Alpha、Beta、Gamma和Delta变体的反应有所提高，尽管对Omicron的反应程度较低。在接受第三剂疫苗的PWH中，B细胞和t细胞免疫力显著增加，包括对已知的关注变体（VOCs）的免疫力。接受抗逆转录病毒治疗（ART）且CD4 t细胞计数良好的人类免疫缺陷病毒（HIV）患者在接种第三剂严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）疫苗后产生有效的交叉变异免疫反应。
People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are few data on longer term responses and the impact of a booster dose. Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed 12 months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µL. Immune responses to the ancestral strain and variants of concern were measured by anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, activation induced marker (AIM) assay, and T-cell proliferation. In total, 54 participants received 2 doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) 1 year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titers (MSD), ACE-2 inhibition, and IgG ELISA results were significantly higher compared to Day 182 titers (P < .0001 for all 3). SARS-CoV-2 specific CD4+ T-cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4+ and CD8+ T-cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron. In PWH receiving a third vaccine dose, there were significant increases in B- and T-cell immunity, including to known variants of concern (VOCs). People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective cross variant immune responses following third dose vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
登录
查看更多内容
DOI：
10.1126/science.abe8499
发表时间：
2020-12-18
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Hou YJ;Chiba S;Halfmann P;Ehre C;Kuroda M;Dinnon KH 3rd;Leist SR;Schäfer A;Nakajima N;Takahashi K;Lee RE;Mascenik TM;Graham R;Edwards CE;Tse LV;Okuda K;Markmann AJ;Bartelt L;de Silva A;Margolis DM;Boucher RC;Randell SH;Suzuki T;Gralinski LE;Kawaoka Y;Baric RS
通讯作者：
Baric RS
DOI：
10.1097/qad.0000000000002836
发表时间：
2021-03-15
期刊：
AIDS (London, England)
影响因子：
--
作者：
Mellor MM;Bast AC;Jones NR;Roberts NW;Ordóñez-Mena JM;Reith AJM;Butler CC;Matthews PC;Dorward J
通讯作者：
Dorward J
DOI：
10.1016/s0140-6736(21)01420-3
发表时间：
2021-07-10
期刊：
Lancet (London, England)
影响因子：
--
作者：
Borobia AM;Carcas AJ;Pérez-Olmeda M;Castaño L;Bertran MJ;García-Pérez J;Campins M;Portolés A;González-Pérez M;García Morales MT;Arana-Arri E;Aldea M;Díez-Fuertes F;Fuentes I;Ascaso A;Lora D;Imaz-Ayo N;Barón-Mira LE;Agustí A;Pérez-Ingidua C;Gómez de la Cámara A;Arribas JR;Ochando J;Alcamí J;Belda-Iniesta C;Frías J;CombiVacS Study Group
通讯作者：
CombiVacS Study Group
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1016/s0140-6736(21)01694-9
发表时间：
2021-09-04
期刊：
Lancet (London, England)
影响因子：
--
作者：
Liu X;Shaw RH;Stuart ASV;Greenland M;Aley PK;Andrews NJ;Cameron JC;Charlton S;Clutterbuck EA;Collins AM;Dinesh T;England A;Faust SN;Ferreira DM;Finn A;Green CA;Hallis B;Heath PT;Hill H;Lambe T;Lazarus R;Libri V;Long F;Mujadidi YF;Plested EL;Provstgaard-Morys S;Ramasamy MN;Ramsay M;Read RC;Robinson H;Singh N;Turner DPJ;Turner PJ;Walker LL;White R;Nguyen-Van-Tam JS;Snape MD;Com-COV Study Group
通讯作者：
Com-COV Study Group